BMP/SMAD1/5/8
Principle
Bone morphogenic protein (BMP) is involved in embryogenesis, development of many organ systems and adult tissue homeostasis. Smads (Smad1/5/8) are activated during the signal transduction and then form a complex with Smad4, translocate into the nucleus where they regulate expression of transcriptional factors and transcriptional coactivators. Deficiency in BMP production or functionality usually leads to marked defects or severe human diseases associated with most organ systems. Monitoring the BMP activity is essential to research of the BMP signaling-associated diseases and conduct drug discovery.
Signosis has established BMP luciferase reporter Hek293 stable cell line that has been stably transfected with pTA-BMP-luciferase reporter vector, which contains 4 repeats of SMAD1/5/8 binding sites, a minimal promoter upstream of the firefly luciferase coding region. Therefore, the cell line can be used as a reporter system for monitoring the activation of BMP triggered by stimuli treatment, enforced gene expression and gene knockdown.
Applications
Drug Screening and Toxicology
Signosis’ BMP/SMAD1/5/8 luciferase reporter cell line offers a powerful tool for drug screening and toxicological assessments, specifically for compounds that modulate BMP signaling. BMPs, including BMP2, BMP4, BMP7, BMP9, and BMP10, are critical regulators of various cellular processes such as differentiation, tissue repair, and immune modulation, and vascularization. The ability to monitor BMP pathway activation with this reporter system enables high-throughput screening of novel small molecules, biologics, and natural products for their effects on BMP signaling, with potential applications in drug discovery and toxicity testing.
This model is especially valuable for evaluating compounds that influence osteogenesis, tissue remodeling, fibrosis, and stem cell differentiation, as well as for identifying potential endocrine-disrupting chemicals or compounds that may affect BMP-related pathways. By quantifying the activity of the BMP/SMAD1/5/8 pathway, researchers can gain insights into how BMP-modulating drugs interact with other signaling cascades and assess their efficacy and safety. Such applications include:
-
High-throughput screening of small molecules, biologics, and natural products for BMP-modulatory effects.
-
Evaluating drug safety by assessing compound interactions with BMP pathways and the potential for off-target effects.
-
Toxicology studies to identify chemicals that may disrupt BMP signaling and lead to adverse effects, including in bone and tissue regeneration.
-
Identifying combination therapies by testing BMP pathway modulators in combination with other oncological or regenerative treatments.
Common inducers and inhibitors that can be used with this model:
-
BMP2, BMP4, BMP7, BMP9, or BMP10 to activate SMAD1/5/8 signaling.
-
Noggin, dorsomorphin, or LDN-193189 to inhibit BMP receptor activation.
-
TGF-β1 for cross-talk studies with other key pathways involved in toxicity, such as those involved in fibrosis or cancer.
Signosis offers the BMP/SMAD1/5/8 luciferase reporter cell line for fast, reproducible drug screening and toxicology studies, aiding researchers in the identification and validation of BMP-targeted therapies and potential safety concerns related to drug candidates.
Benefits
Firefly Luciferase Reporter Stable Cell Lines
Signosis' cell line for monitoring NRF2 binding and activation using the standard Firefly Luciferase as the reporter.
Secreted Luciferase Reporter Stable Cell Lines
Secreted Luciferase Reporters Stable Cell Lines that offer many unique advantages over the standard Firefly Luciferase reporter. Secreted Luciferases allow for noninvasive, real-time monitoring of gene activation and long-term continuous studies on he same cell population, all while skipping the cell lysis step which will streamline your experimental procedures.
Name | SKU | Price (USD$) |
|---|---|---|
SMAD/BMP Secreted Responsive Luciferase Reporter HEK293 Stable Cell Line SL-4051 | SL-4051 | $3,870.00 |
